Generation Bio Co. –  Company continues to advance its strategy to develop first-in-class treatments for T cell-driven autoimmune diseases using its cell-targeted lipid nanoparticle (ctLNP) technology to deliver siRNA –  Lead target and portfolio strategy to be announced mid-2025 –  Cash balance of $157.6 million expected to fund operations into 2H 2027 CAMBRIDGE, MASS., May